From: Current advances and outlooks in immunotherapy for pancreatic ductal adenocarcinoma
mAb | Condition | Target | Cells | Mechanism | Status | Reference |
---|---|---|---|---|---|---|
SS1(dsFv)-PE38 (SS1P) | An anti-mesothelin Fv genetically fused with a truncated pseudomonas exotoxin, PE38 | Mesothelin | Cancer cells | PE38 is internalized into and kills cancer cells through inhibition of protein synthesis by ADP ribosylation and inactivation of elongation factor 2 | Clinical trials | NCT01362790; NCT00006981 |
MORAb-009 | Heavy and light chain variable regions of a mouse anti-mesothelin single chain Fv grafted to human IgG1 and κ constant regions | Mesothelin | Cancer cells | Inhibits the adhesion between cells expressing mesothelin and MUC16 as well as mediates ADCC | Clinical trials | NCT00570713; NCT00325494; NCT01521325; NCT01413451 |
BAY94–9343 | An ADC consisting of a human anti-mesothelin antibody conjugated to a tubulin inhibitor, DM4 | Mesothelin | Cancer cells | Binds to human mesothelin and induces antigen internalization | Clinical trials | NCT03023722; NCT03816358; NCT03102320 |
GP1.4 | Monoclonal antibody | MUC1 | Cancer cells | Induces MUC1 internalization and inhibits ERK signalling, resulting in the suppression of PDAC cell proliferation and migration | Preclinical study | [78] |
A novel produced monoclonal antibody | Monoclonal antibody | MUC1-C | Cancer cells | Induces MUC1 internalization and inhibits ERK signalling, resulting in the suppression of PDAC cell proliferation and migration | Preclinical study | [79] |
A.4.6.1 | Murine-derived monoclonal antibody | VEGF | Cancer cells | Inhibits the angiogenesis of tumours | Preclinical study | [80] |
Erlotinib | Monoclonal antibody | EGFR | Cancer cells | Inhibits the angiogenesis of tumours | Clinical trials | NCT00810719; NCT02154737; NCT02694536; NCT01782690; NCT00614653; NCT00640978; NCT00565487; NCT00313560; NCT01608841; NCT01303029 |
Bevacizumab | Monoclonal antibody | VEGF | Cancer cells | Inhibits the angiogenesis of tumours | Clinical trials | NCT00614653; NCT00047710; NCT00460174; NCT00365144; NCT00410774; NCT00417976; NCT00112528; NCT00602602; NCT00126633; NCT00366457 |
9E1 | Monoclonal antibody | AnxA6 | Cancer cells, potential stromal cells | Reduces the expression of MMP-9 and/or interferes with ERK and MEK signalling | Preclinical study | [81] |
Demcizumab | Monoclonal antibody | DLL4 | CSCs | Decreases CSC frequency and interferes with angiogenesis | Clinical trials | [82]; NCT01189929; NCT02289898 |
Clivatuzumab (PAM4) | 131I-labelled,90Y-labelled | MUC1 | Cancer cells | Radioimmunotherapy | Clinical trials | [83] |
TF10 (A humanized recombinant structure) | 90Y-labelled | MUC1 | Cancer cells | Radioimmunotherapy | Preclinical study | [83] |
C595 | 213Bi-labelled | MUC1 | Cancer cells | Radioimmunotherapy | Preclinical study | [83] |
CC49 | 131I-labelled | TAG-72 | Cancer cells | Radioimmunotherapy | Preclinical study | [83] |
EGFR antibody | 177Lu-labelled | EGFR | Cancer cells | Radioimmunotherapy | Preclinical study | [83] |
Trastuzumab | 213Bi-labelled | HER2 | Cancer cells | Radioimmunotherapy | Preclinical study | [83] |
TNT3 antibodies | 213Bi-labelled | Single-strand DNA and RNA | Released from necrotic cells | Radioimmunotherapy | Preclinical study | [83] |
KAb201 | 131I-labelled | CEA | Cancer cells | Radioimmunotherapy | Clinical trial | [83] |
MN-14 | 131I-labelled | CEA | Cancer cells | Radioimmunotherapy | Clinical trial | [83] |
TCMC-Trastuzumab | 212Pb-labelled | HER2 | Cancer cells | Radioimmunotherapy | Clinical trial | [83] |
059–053 | 90Y-labelled | CD147 | Cancer cells | Radioimmunotherapy | Preclinical trial | [84] |
376.96 | 212Pb-labelled | B7-H3 | Cancer cells | Radioimmunotherapy | Preclinical trial | [85] |
TIBs derived IgG | Unidentified multiclonal antibody | G12 mutation-derived epitopes | Cancer cells | Targets mutation-derived and personalized antigens | Preclinical study | [86] |